Drugs / Bempegaldesleukin
Bempegaldesleukin
also known as
NKTR 214 · BEMPEG · Aldesleukin prodrug nktr-214 · Bempegaldesleukina · Bempegaldesleukine · NKTR-214 PRODRUG
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04646044 | Nov 2020 → May 2021 | COVID-19 | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04955262 | Aug 2019 → Jun 2021 | metastatic melanoma | Nektar Therapeutics | Withdrawn | No outcome recorded |
| Phase 1 | NCT03835533 | Jun 2019 → Oct 2022 | prostate carcinoma | Parker Institute for Cancer Immunotherapy | Completed | No outcome recorded |
| Phase 1 | NCT03745807 | Apr → Dec 2019 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03772288 | Apr 2019 → Nov 2021 | non-Hodgkin lymphoma | Calithera Biosciences, Inc | Withdrawn | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT04730349 | Jun 2021 → Jun 2022 | Ewing sarcoma, ependymoma, high grade astrocytic tumor, lymphoid hemopathy +3 | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1/2 | NCT04052204 | Dec 2019 → Sep 2020 | castration-resistant prostate carcinoma, head and neck squamous cell carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 1/2 | NCT03548467 | Apr 2018 → Jan 2023 | — | Nykode Therapeutics ASA | Completed | No outcome recorded |
| Phase 1/2 | NCT03138889 | Jun 2017 → Jul 2022 | non-small cell lung carcinoma | Nektar Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT02983045 | Dec 2016 → Apr 2022 | gastric cancer, hormone receptor-positive breast cancer, melanoma, non-small cell lung carcinoma +3 | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT02869295 | Dec 2015 → Oct 2018 | cancer of unknown primary site | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07156643 | Oct 2025 → Oct 2030 expected | soft tissue sarcoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04936841 | Aug 2021 → Oct 2022 | head and neck squamous cell carcinoma | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 2 | NCT03785925 | Apr 2019 → Feb 2022 | metastatic neoplasm, urinary bladder neoplasm | Nektar Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03282344 | Sep 2017 → Sep 2026 expected | sarcoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04969861 | Mar → Apr 2022 | head and neck cancer | Nektar Therapeutics | Terminated | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04410445 | Jul 2020 → Sep 2022 | cutaneous melanoma | Nektar Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT04209114 | Feb 2020 → Jun 2023 | infiltrating bladder urothelial carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT03729245 | Dec 2018 → Jan 2022 | renal cell carcinoma | Nektar Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT03635983 | Sep 2018 → Nov 2021 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03435640 Background | Mar 2018 → May 2022 | colorectal cancer, cutaneous neuroendocrine carcinoma, head and neck squamous cell carcinoma, melanoma +3 | Nektar Therapeutics | Terminated | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-04-14 | Bristol-Myers Squibb | Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) bms.com ↗ |
| 2022-03-14 | Bristol-Myers Squibb | Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma bms.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bempegaldesleukin | “NKTR-214 (bempegaldesleukin) is a novel IL2 pathway agonist, designed to provide sustained signaling through heterodimeric IL2 receptor βγ to drive increased proliferation and...” PMID 30988166 ↗ Apr 201912“OBJECTIVE: To evaluate the immunostimulatory interleukin-2 cytokine prodrug bempegaldesleukin (BEMPEG) plus nivolumab in patients with advanced/mUC from the phase 2 multicenter...” PMID 35643589 ↗ May 2022 |
| Known as | Aldesleukin prodrug nktr-214 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298058 ↗ |
| Known as | BEMPEG | “This is a multicenter, randomized, open-label, Phase 2/3 study that will evaluate the efficacy and safety of bempegaldesleukin (BEMPEG; NKTR-214) combined with pembrolizumab...” NCT04969861 ↗3“A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care...” NCT04646044 ↗ “OBJECTIVE: To evaluate the immunostimulatory interleukin-2 cytokine prodrug bempegaldesleukin (BEMPEG) plus nivolumab in patients with advanced/mUC from the phase 2 multicenter...” PMID 35643589 ↗ May 2022 “Bempegaldesleukin (BEMPEG), a pegylated interleukin-2 (IL-2) cytokine prodrug, demonstrated efficacy in the phase II PIVOT-02 trial.” PMID 37651676 ↗ Aug 2023 |
| Known as | Bempegaldesleukina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298058 ↗ |
| Known as | Bempegaldesleukine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298058 ↗ |
| Known as | NKTR 214 | “This is a multicenter, randomized, open-label, Phase 2/3 study that will evaluate the efficacy and safety of bempegaldesleukin (BEMPEG; NKTR-214) combined with pembrolizumab...” NCT04969861 ↗11“Here, we report a patient with metastatic melanoma who had a durable clinical response after treatment with the programmed cell death protein 1 inhibitor, nivolumab, combined...” PMID 33298619 ↗ Dec 2020 “A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care...” NCT04646044 ↗ |
| Known as | NKTR-214 PRODRUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298058 ↗ |
| Action | Activate | “NKTR-214 (bempegaldesleukin) is a novel IL2 pathway agonist” PMID 30988166 ↗ Apr 2019 |
| Modality | Protein / enzyme biologic | “NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.” PMID 30988166 ↗ Apr 2019 |
| Route | Intravenous | “Patients received BEMPEG 0.006 mg/kg plus nivolumab 360 mg intravenously every 3 wk.” PMID 35643589 ↗ May 2022 |